Phase 2 N=18 A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.
HIV Infections
Primary: Plasma Trough Concentrations (Ctrough) for Saquinavir — 645; 1860 ng/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=12 Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma
Recurrent Childhood Medulloblastoma
Primary: Objective Response (CR+PR) Sustained for ≥ 8 Weeks — 1 participants
Phase 2 N=15 Insulin Complexation With Hydroxypropyl-beta-cyclodextrin: Use of the Complex in Gel for Healing of Pressure Ulcers
Pressure Ulcer · Wound
Primary: Efficacy Index (%EI) — 82.76; 43.66; 14.58 percentage (%)
Phase 2 N=13 Effect of Oral Administration of Methylene Blue MMX Tablets on Double Stranded DNA
Colorectal Cancer
Primary: Gamma H2AX Histone Levels in Colonic Biopsy During Standard White Light Colonoscopy and Colonoscopy for Which Methylene Blue MMX Was Taken Prior to Initiating the…
Phase 2 N=33 Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer
Small Cell Lung Cancer · Lung Cancer · SCLC
Primary: 8-Week Progression-Free Rate — 0.567 proportion of patients
Phase 2 N=40 Nasal Spray With Glucose Oxidase Preventing Common Cold in Pre-school Children
Upper Respiratory Tract Infections
Primary: Respiratory Infectious Symptoms — 9; 13; 10; 13 days — p=>0.05
Phase 2 N=314 Strategies To Prevent Pneumonia 2 (SToPP2)
Infections, Hospital · Ventilator-Associated Pneumonia · Mechanical Ventilation Complication
Primary: Development of VAP (Clinical Pulmonary Infection Score) — 4.13; 4.45 units on a scale — p=0.1763
Phase 2 N=304 Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim
Breast Cancer
Primary: Maximum Patient-reported Bone Pain in Cycle 1 — 3.2; 3.5 units on a scale — p=0.3479
Phase 2 N=96 Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074
Alzheimer's Disease
Primary: Differences in ∆sCD40L Levels Between CHF 5074 Doses and Placebo at Any Specific Time Point — 270.28; 403.22; -1293.42; 242.49 pg/ml
Phase 2 N=77 Parent-Based Treatment for Pediatric Overweight
Overweight · Obesity
Primary: BMI Z Score — 2.3; 2.4 Z-score
Phase 2 N=171 Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
Acquired Immunodeficiency Syndrome · HIV Infections
Primary: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 — 88.4; 89.7 percentage of participants — p=0.58
Phase 2 N=83 Efficacy Study in Allergic Rhinitis Patients After Intranasal Administration of AZD8848
Allergic Rhinitis
Primary: Mean of Reflective (10 Min) Total Nasal Symptom Score (TNSS) — 4.52; 4.97; 4.69 Scores on a scale
Phase 2 N=45 Evaluation of Robot Assisted Neuro-Rehabilitation
Stroke
Primary: Fugl-Meyer Motor Upper Extremity Assessment — 2.7; 3.7; 3.7; 3.5 units on a scale — p=<0.05
Phase 2 N=52 A Study of Avastin (Bevacizumab) Plus Herceptin (Trastuzumab) in Patients With Primary Inflammatory HER2-Positive Breast Cancer.
Breast Cancer
Primary: Percentage of Participants With a Pathological Complete Response (PCR) According to the Sataloff Classification — 63.46 percentage of participants
Phase 2 N=11 Dietary Nitrate and Exercise to Augment Exercise Training Benefits in Subjects With DM+PAD
Peripheral Arterial Disease · Type II Diabetes Mellitus
Primary: Change in Exercise Capacity - Maximal Oxygen Capacity (VO2peak) — 0.85; -0.15 ml/kg/min